Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in adults worldwide, characterized by the abnormal thickening of the glomerular basement membrane — the microscopic filtration barrier within the kidney. For decades, its diagnosis required invasive kidney biopsy, its causes remained poorly understood, and its management relied on broadly immunosuppressive regimens with significant side effects and inconsistent outcomes. A single landmark discovery changed all of that. The identification of phospholipase A2 receptor (PLA2R) as a primary disease-driving antigen in 2009 marked a pivotal turning point, fundamentally reshaping how nephrologists diagnose, monitor, and treat this condition. The International Society of Nephrology has played a central role in disseminating the scientific advances that followed, integrating this knowledge into globally recognized clinical guidelines and supporting the evidence base that now guides practice worldwide.
Understanding Membranous Nephropathy: The Basics
To appreciate the significance of recent advances, it helps to understand what membranous nephropathy actually is and how it affects the kidney. The glomeruli — tiny clusters of capillaries responsible for filtering blood — are protected and regulated by a delicate structure called the glomerular basement membrane. In membranous nephropathy, immune complexes (combinations of antibodies and their target proteins called antigens) accumulate on the outer surface of this membrane. This triggers a complement-mediated inflammatory cascade that gradually damages the membrane’s integrity, allowing protein — particularly albumin — to leak from the blood into the urine.
This protein loss, known as proteinuria, is the hallmark of nephrotic syndrome. Patients typically experience heavy protein spilling into the urine (greater than 3.5 grams per day), low albumin levels in the blood (hypoalbuminemia), significant swelling (edema), elevated blood lipids (hyperlipidemia), and an increased risk of blood clots. Left untreated or poorly managed, MN can progress to chronic kidney disease and, in some patients, kidney failure requiring dialysis or transplantation.
Membranous nephropathy is categorized into two broad forms:
- Primary (idiopathic) MN — driven by autoimmune processes targeting specific antigens in the kidney, with no identifiable systemic cause
- Secondary MN — arising as a consequence of another condition such as systemic lupus erythematosus, hepatitis B or C infection, certain medications, or malignancy
Distinguishing between these two forms is clinically essential, as their treatment pathways differ substantially. Before the advent of serological biomarkers, this distinction relied almost entirely on kidney biopsy findings and clinical context.
The PLA2R Discovery: A Paradigm Shift
In 2009, a research team led by Beck and colleagues published a transformative study in the New England Journal of Medicine identifying the M-type phospholipase A2 receptor (PLA2R) as the primary autoantigen targeted in primary membranous nephropathy. PLA2R is a transmembrane receptor expressed on the surface of glomerular podocytes — the specialized cells that form the outermost layer of the glomerular filtration barrier. In patients with primary MN, the immune system produces IgG4-class antibodies directed against this receptor, leading to immune complex deposition and the cascade of injury that defines the disease.
This discovery was scientifically profound for several reasons. It established primary MN as a true autoimmune disease with a defined molecular target, rather than an idiopathic disorder of unknown mechanism. It opened the door to non-invasive serological testing — a blood test to detect circulating anti-PLA2R antibodies — and it provided a measurable biomarker that could track disease activity over time.
Today, anti-PLA2R antibodies are detectable in approximately 70 to 80 percent of patients with primary MN, with a high specificity that allows clinicians to distinguish primary from secondary MN without the need for repeated invasive kidney biopsy. This is a meaningful advance for patients, reducing procedural burden, risk, and cost while enabling more rapid diagnostic decisions.
How Anti-PLA2R Testing Works in Clinical Practice
Anti-PLA2R antibody testing is performed on a blood sample using two principal methods: enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IIF). Both platforms detect IgG antibodies targeting the PLA2R antigen, though they differ in sensitivity and the quantitative detail they provide.
Diagnostic Applications
When a patient presents with nephrotic syndrome and kidney biopsy reveals features consistent with membranous nephropathy, a positive anti-PLA2R antibody test strongly supports a diagnosis of primary MN. In many centers, a positive serology in the appropriate clinical context can reduce — though not always eliminate — the need for biopsy, particularly in patients for whom the procedure carries elevated risk.
A negative anti-PLA2R result, however, does not rule out primary MN; approximately 20 to 30 percent of primary MN cases are seronegative for this specific antibody. In such patients, testing for additional antigens (discussed below) or relying on biopsy findings remains essential.
Monitoring Disease Activity and Treatment Response
One of the most valuable clinical applications of anti-PLA2R testing is longitudinal monitoring. A prospective validation study published in the Journal of the American Society of Nephrology by Ruggenenti and colleagues in 2015 demonstrated that serological remission — defined as the disappearance or near-disappearance of circulating anti-PLA2R antibodies — preceded clinical remission of proteinuria by a median of approximately 8.6 months. This observation has important practical implications:
- A patient whose antibody titers are falling may eventually achieve proteinuria remission even before it becomes apparent on standard urine tests
- Persistent antibody positivity after treatment predicts relapse following cessation of immunosuppressive therapy
- Serial antibody monitoring can guide decisions about when to continue, adjust, or discontinue treatment
This evidence rationalized the integration of anti-PLA2R titer monitoring into treatment decision algorithms, supporting a more individualized and data-driven approach to MN management.
ISN and KDIGO Guidelines: Translating Science into Global Practice
The International Society of Nephrology has been instrumental in ensuring that advances in the understanding of membranous nephropathy are systematically translated into clinical practice guidelines accessible to nephrologists worldwide. ISN (International Society of Nephrology) is closely affiliated with the Kidney Disease: Improving Global Outcomes (KDIGO) initiative, which produces evidence-based clinical practice guidelines adopted internationally.
Anti-PLA2R serology was incorporated into the KDIGO Clinical Practice Guidelines for Glomerulonephritis, first published in 2012 and significantly updated in 2021 (Rovin et al., Kidney International). These guidelines formalized the diagnostic and monitoring algorithm for MN, positioning anti-PLA2R antibody testing as a central component of initial workup and ongoing management. ISN-affiliated nephrologists contributed substantially to the evidence synthesis underlying these recommendations, reinforcing the organization’s role not merely as a disseminator of knowledge but as an active participant in generating the global evidence base.
The table below summarizes how anti-PLA2R antibody status informs clinical decision-making in primary MN:
| Clinical Scenario | Anti-PLA2R Status | Clinical Interpretation |
|---|---|---|
| Initial diagnosis with nephrotic syndrome | Positive | Strongly supports primary MN; may reduce need for immediate repeat biopsy |
| Initial diagnosis with nephrotic syndrome | Negative | Investigate secondary causes; consider additional antigen testing or biopsy |
| During immunosuppressive treatment | Declining titers | Suggests immunological response; clinical remission likely to follow |
| During immunosuppressive treatment | Persistently elevated | Inadequate treatment response; consider regimen adjustment |
| After treatment cessation | Re-elevation of titers | Predicts clinical relapse; warrants close monitoring and possible retreatment |
Beyond PLA2R: A Growing Family of Target Antigens
The discovery of PLA2R opened a new chapter in the biology of membranous nephropathy, prompting researchers to search for the antigens responsible for primary MN in the 20 to 30 percent of patients who test negative for anti-PLA2R antibodies. The results have been remarkable.
In 2014, Tomas and colleagues published in the New England Journal of Medicine the identification of thrombospondin type-1 domain-containing 7A (THSD7A) as a second major autoantigen in primary MN. Importantly, THSD7A-associated MN has been linked to a higher prevalence of underlying malignancy, making it clinically essential to screen THSD7A-positive patients for occult cancer.
More recently, research led by Sethi and colleagues, published in Kidney International between 2020 and 2023, described a series of additional target antigens including:
- NELL-1 (Neural EGFL-like 1) — associated with a distinct histological pattern and clinical behavior
- PCDH7 (Protocadherin 7) — identified in a subset of seronegative primary MN patients
- SEMA3B (Semaphorin 3B) — notably associated with MN in children and young adults
- Several other less common antigens still under active investigation
These discoveries have fundamentally reframed primary membranous nephropathy: rather than a single disease, it is now understood as a heterogeneous group of antigen-specific autoimmune glomerulopathies, each potentially with its own clinical associations, course, and optimal treatment approach. This evolving landscape places increasing demands on diagnostic laboratories and clinicians to stay current with emerging biomarkers and their clinical correlates — an area where global organizations like the International Society of Nephrology continue to play an essential educational and standard-setting role.
Treatment Advances: The Rise of B-Cell Depleting Therapies
Given that primary MN is driven by pathogenic antibody production, targeting the B cells responsible for generating those antibodies represents a rational and precise therapeutic strategy. The most significant advance in this domain has been the widespread adoption of rituximab, a monoclonal antibody that selectively depletes CD20-positive B cells.
The MENTOR trial, published in the New England Journal of Medicine in 2019 by Fervenza and colleagues, provided the definitive evidence base for rituximab in primary MN. This randomized controlled trial compared rituximab directly with cyclosporine — at the time the most commonly used immunosuppressive agent — in patients with primary MN and persistent nephrotic-range proteinuria. The results were compelling:
- Rituximab was superior to cyclosporine in achieving complete or partial proteinuria remission at 24 months
- Rituximab-treated patients maintained remission after therapy withdrawal, whereas cyclosporine-treated patients showed high relapse rates after cessation
- The durability of rituximab’s benefit reflected its mechanism: by depleting B cells and suppressing anti-PLA2R antibody production, it addressed the underlying immunological driver of the disease rather than merely suppressing its downstream effects
The MENTOR trial, aligned with supporting evidence from several other studies, established rituximab as the preferred first-line immunosuppressive agent for primary MN in current ISN-aligned clinical practice guidelines. This represents a significant departure from older treatment protocols that relied heavily on combinations of corticosteroids with alkylating agents such as cyclophosphamide or chlorambucil — regimens associated with substantial toxicity and long-term health risks.
Other Emerging Therapies
Beyond rituximab, the anti-PLA2R-centered understanding of MN has catalyzed interest in other B-cell-targeted or antibody-depleting strategies. Obinutuzumab, a next-generation anti-CD20 antibody with enhanced B-cell depletion characteristics, is under investigation. Belimumab, which targets the B-cell survival factor BAFF, and other agents targeting plasma cell longevity are areas of active research interest. The emerging availability of antigen-specific biomarkers makes MN an attractive condition for testing novel precision therapies — a field in which ISN continues to foster collaborative international research networks.
Implications for Patients and Healthcare Systems
The clinical advances reviewed here are not merely academic; they carry substantial implications for patients and for the healthcare systems serving them. Serological diagnosis reduces the number of invasive procedures patients must undergo. Biomarker-guided monitoring allows treatment to be tailored more precisely to individual disease activity, potentially reducing cumulative immunosuppressive exposure. The availability of a highly effective, targeted therapy in rituximab offers many patients better outcomes with fewer toxic side effects compared to older regimens.
For low- and middle-income countries, where access to kidney biopsy facilities and specialized pathology services may be limited, the availability of validated serological testing for anti-PLA2R antibodies represents an especially meaningful advance. A blood test that can be performed and interpreted without specialized biopsy infrastructure lowers the barrier to accurate MN diagnosis in resource-constrained settings — consistent with the International Society of Nephrology’s broader mission to improve kidney health equity worldwide.
Conclusion
The story of membranous nephropathy over the past fifteen years is one of the most instructive examples of how targeted basic science discovery can transform clinical nephrology. From the identification of PLA2R as a disease antigen to the validation of anti-PLA2R antibody testing as a clinical biomarker, from the discovery of multiple additional antigens to the demonstration of rituximab’s superiority in randomized trials, the field has undergone a genuine revolution. ISN (International Society of Nephrology) has served as a vital conduit throughout this process — facilitating the translation of scientific findings into globally adopted guidelines, supporting the clinicians and researchers advancing the field, and ensuring that improved diagnostic and therapeutic standards reach patients across diverse healthcare settings. As the antigen landscape of MN continues to expand and novel therapies emerge from the pipeline, ongoing engagement with organizations like the International Society of Nephrology will remain essential for nephrologists seeking to provide evidence-based, patient-centered care. The era of precision medicine in membranous nephropathy is not a distant prospect — it is already underway.